Sarah Billups
Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 19 | 2025 | 260 | 4.280 |
Why?
| | Hypertension | 10 | 2026 | 1272 | 2.410 |
Why?
| | Osteoporosis | 4 | 2023 | 240 | 2.190 |
Why?
| | Primary Health Care | 14 | 2026 | 1776 | 1.770 |
Why?
| | Remote Consultation | 2 | 2026 | 67 | 1.700 |
Why?
| | Antihypertensive Agents | 6 | 2026 | 519 | 1.630 |
Why?
| | Osteoporotic Fractures | 3 | 2023 | 62 | 1.550 |
Why?
| | Bone Density Conservation Agents | 4 | 2022 | 83 | 1.510 |
Why?
| | Quality Improvement | 4 | 2026 | 1354 | 1.450 |
Why?
| | Drug Monitoring | 9 | 2026 | 399 | 1.400 |
Why?
| | Osteoporosis, Postmenopausal | 3 | 2022 | 41 | 1.140 |
Why?
| | Medicare Part C | 2 | 2026 | 39 | 1.040 |
Why?
| | Gout Suppressants | 2 | 2025 | 18 | 1.000 |
Why?
| | Gout | 2 | 2025 | 34 | 0.970 |
Why?
| | Pharmaceutical Services | 7 | 2020 | 76 | 0.950 |
Why?
| | Dermatologists | 1 | 2025 | 7 | 0.920 |
Why?
| | Acne Vulgaris | 1 | 2025 | 25 | 0.910 |
Why?
| | Xanthine Oxidase | 1 | 2025 | 79 | 0.890 |
Why?
| | Blood Pressure | 4 | 2026 | 1765 | 0.890 |
Why?
| | Drug Costs | 2 | 2025 | 116 | 0.880 |
Why?
| | Dermatologic Agents | 1 | 2025 | 69 | 0.880 |
Why?
| | Rheumatic Diseases | 1 | 2026 | 101 | 0.840 |
Why?
| | Blood Pressure Determination | 3 | 2026 | 143 | 0.820 |
Why?
| | Rheumatology | 1 | 2026 | 136 | 0.820 |
Why?
| | Guideline Adherence | 4 | 2025 | 594 | 0.780 |
Why?
| | Retrospective Studies | 26 | 2026 | 17438 | 0.770 |
Why?
| | Medicare | 2 | 2026 | 920 | 0.770 |
Why?
| | Physicians, Primary Care | 1 | 2025 | 210 | 0.760 |
Why?
| | Maternal Health Services | 1 | 2024 | 100 | 0.730 |
Why?
| | Pharmacy Service, Hospital | 11 | 2017 | 90 | 0.730 |
Why?
| | Enzyme Inhibitors | 2 | 2025 | 823 | 0.720 |
Why?
| | Practice Patterns, Physicians' | 5 | 2025 | 1408 | 0.710 |
Why?
| | Aged | 39 | 2026 | 26432 | 0.700 |
Why?
| | Medication Adherence | 2 | 2025 | 535 | 0.700 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 209 | 0.660 |
Why?
| | Communicable Diseases | 1 | 2023 | 166 | 0.660 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 272 | 0.610 |
Why?
| | Patient-Centered Care | 1 | 2024 | 553 | 0.570 |
Why?
| | Female | 50 | 2026 | 79499 | 0.560 |
Why?
| | Emergency Service, Hospital | 5 | 2023 | 2363 | 0.540 |
Why?
| | Cohort Studies | 11 | 2025 | 6077 | 0.530 |
Why?
| | Aged, 80 and over | 12 | 2026 | 8391 | 0.520 |
Why?
| | Humans | 63 | 2026 | 146342 | 0.520 |
Why?
| | Diphosphonates | 2 | 2015 | 68 | 0.520 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2016 | 13 | 0.510 |
Why?
| | Health Services Accessibility | 1 | 2026 | 1107 | 0.500 |
Why?
| | Middle Aged | 30 | 2026 | 36619 | 0.500 |
Why?
| | Patient Transfer | 1 | 2020 | 224 | 0.500 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2014 | 69 | 0.500 |
Why?
| | Male | 45 | 2026 | 73396 | 0.490 |
Why?
| | Pharmacy Residencies | 1 | 2016 | 10 | 0.480 |
Why?
| | Community Pharmacy Services | 2 | 2013 | 46 | 0.470 |
Why?
| | Research | 2 | 2016 | 421 | 0.460 |
Why?
| | Colorado | 11 | 2026 | 4595 | 0.460 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 914 | 0.450 |
Why?
| | Telephone | 1 | 2015 | 175 | 0.410 |
Why?
| | Hospitals, Veterans | 9 | 2001 | 256 | 0.400 |
Why?
| | Pharmacies | 1 | 2014 | 40 | 0.390 |
Why?
| | Correspondence as Topic | 2 | 2015 | 16 | 0.380 |
Why?
| | Patient Satisfaction | 5 | 2013 | 706 | 0.380 |
Why?
| | Patient Compliance | 5 | 2009 | 589 | 0.380 |
Why?
| | Adult | 19 | 2026 | 41087 | 0.360 |
Why?
| | United States | 18 | 2026 | 16136 | 0.360 |
Why?
| | Health Maintenance Organizations | 4 | 2014 | 106 | 0.360 |
Why?
| | Professional Role | 5 | 2020 | 172 | 0.350 |
Why?
| | Prescription Drugs | 1 | 2013 | 110 | 0.350 |
Why?
| | Delivery of Health Care, Integrated | 5 | 2018 | 305 | 0.330 |
Why?
| | Insurance, Health | 1 | 2014 | 318 | 0.330 |
Why?
| | Cost Savings | 2 | 2015 | 87 | 0.320 |
Why?
| | Neuromuscular Agents | 1 | 2011 | 46 | 0.310 |
Why?
| | Drug Prescriptions | 4 | 2020 | 314 | 0.300 |
Why?
| | Drug Therapy | 2 | 2000 | 85 | 0.300 |
Why?
| | Nortriptyline | 1 | 2009 | 9 | 0.290 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2009 | 4 | 0.290 |
Why?
| | Amitriptyline | 1 | 2009 | 25 | 0.290 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 30 | 0.290 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 44 | 0.280 |
Why?
| | Referral and Consultation | 2 | 2026 | 881 | 0.270 |
Why?
| | Perception | 2 | 2023 | 373 | 0.270 |
Why?
| | Tetrahydronaphthalenes | 2 | 1998 | 34 | 0.270 |
Why?
| | HIV Infections | 1 | 2023 | 3215 | 0.260 |
Why?
| | Calcium Channel Blockers | 2 | 1998 | 165 | 0.250 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1408 | 0.250 |
Why?
| | Electronic Health Records | 4 | 2026 | 1210 | 0.250 |
Why?
| | Benzimidazoles | 2 | 1998 | 191 | 0.250 |
Why?
| | Fractures, Bone | 1 | 2012 | 436 | 0.240 |
Why?
| | Cholesterol, LDL | 2 | 2025 | 363 | 0.240 |
Why?
| | Managed Care Programs | 2 | 2013 | 137 | 0.230 |
Why?
| | Pilot Projects | 2 | 2023 | 1888 | 0.230 |
Why?
| | Lovastatin | 1 | 2005 | 37 | 0.230 |
Why?
| | American Heart Association | 2 | 2020 | 364 | 0.220 |
Why?
| | Simvastatin | 1 | 2005 | 58 | 0.220 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2018 | 266 | 0.210 |
Why?
| | Heart Diseases | 1 | 2008 | 343 | 0.210 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2025 | 449 | 0.210 |
Why?
| | Uric Acid | 1 | 2025 | 167 | 0.210 |
Why?
| | Health Care Costs | 2 | 2014 | 423 | 0.200 |
Why?
| | Patient Acceptance of Health Care | 2 | 2023 | 881 | 0.200 |
Why?
| | Bone Density | 2 | 2022 | 494 | 0.200 |
Why?
| | Academic Medical Centers | 2 | 2024 | 561 | 0.200 |
Why?
| | Cholesterol | 2 | 2020 | 411 | 0.200 |
Why?
| | Ambulatory Care | 6 | 2010 | 628 | 0.200 |
Why?
| | Migraine Disorders | 2 | 2020 | 109 | 0.200 |
Why?
| | Young Adult | 6 | 2025 | 14330 | 0.190 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 134 | 0.190 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 278 | 0.180 |
Why?
| | Wounds and Injuries | 1 | 2011 | 959 | 0.180 |
Why?
| | Denosumab | 1 | 2022 | 10 | 0.180 |
Why?
| | Patient Care Team | 3 | 2024 | 701 | 0.180 |
Why?
| | Program Evaluation | 1 | 2026 | 952 | 0.170 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1591 | 0.170 |
Why?
| | Serotonin 5-HT1 Receptor Agonists | 1 | 2020 | 3 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2025 | 410 | 0.170 |
Why?
| | Aspirin | 1 | 2024 | 405 | 0.160 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 503 | 0.160 |
Why?
| | Diabetes Mellitus | 2 | 2013 | 1101 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1221 | 0.150 |
Why?
| | Health Promotion | 1 | 2026 | 786 | 0.140 |
Why?
| | Adolescent | 5 | 2025 | 22557 | 0.140 |
Why?
| | Quality of Health Care | 1 | 2024 | 702 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2023 | 536 | 0.140 |
Why?
| | Student Health Services | 1 | 2018 | 15 | 0.140 |
Why?
| | Antimanic Agents | 1 | 2018 | 14 | 0.140 |
Why?
| | Lithium Compounds | 1 | 2018 | 11 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2024 | 609 | 0.140 |
Why?
| | Angina Pectoris | 1 | 1998 | 76 | 0.130 |
Why?
| | Product Surveillance, Postmarketing | 1 | 1998 | 74 | 0.130 |
Why?
| | Drug Approval | 1 | 1998 | 94 | 0.130 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2219 | 0.130 |
Why?
| | Preceptorship | 1 | 2018 | 68 | 0.130 |
Why?
| | Antidepressive Agents | 2 | 2017 | 235 | 0.130 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1219 | 0.130 |
Why?
| | Data Collection | 4 | 2014 | 650 | 0.130 |
Why?
| | Students, Pharmacy | 1 | 2018 | 96 | 0.130 |
Why?
| | Drug Interactions | 4 | 2012 | 405 | 0.120 |
Why?
| | Chronic Disease | 5 | 2026 | 1827 | 0.120 |
Why?
| | Quality of Life | 4 | 2001 | 3200 | 0.110 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 185 | 0.110 |
Why?
| | Pharmaceutical Preparations | 2 | 2016 | 172 | 0.110 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 279 | 0.110 |
Why?
| | Administration, Oral | 2 | 2015 | 872 | 0.110 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 10 | 0.110 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 640 | 0.110 |
Why?
| | Hematinics | 1 | 2014 | 22 | 0.100 |
Why?
| | Risk Factors | 10 | 2025 | 10921 | 0.100 |
Why?
| | Patient Readmission | 1 | 2020 | 778 | 0.100 |
Why?
| | Renal Insufficiency | 2 | 2015 | 173 | 0.100 |
Why?
| | United States Department of Veterans Affairs | 5 | 2001 | 777 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2013 | 5439 | 0.100 |
Why?
| | Reminder Systems | 1 | 2015 | 149 | 0.100 |
Why?
| | Patient Discharge | 1 | 2020 | 997 | 0.100 |
Why?
| | Educational Measurement | 1 | 2016 | 331 | 0.090 |
Why?
| | Colchicine | 1 | 2012 | 20 | 0.090 |
Why?
| | Outpatients | 1 | 2016 | 440 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1942 | 0.090 |
Why?
| | Anemia | 1 | 2014 | 190 | 0.090 |
Why?
| | Hematologic Diseases | 1 | 2012 | 66 | 0.090 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 92 | 0.090 |
Why?
| | Lipids | 1 | 2017 | 714 | 0.090 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 279 | 0.090 |
Why?
| | Health Expenditures | 1 | 2014 | 198 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 5899 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2009 | 1036 | 0.090 |
Why?
| | Hyperlipidemias | 3 | 2017 | 120 | 0.080 |
Why?
| | Hospitalization | 2 | 2018 | 2475 | 0.080 |
Why?
| | Evaluation Studies as Topic | 1 | 2011 | 161 | 0.080 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 138 | 0.080 |
Why?
| | Job Satisfaction | 1 | 2013 | 236 | 0.080 |
Why?
| | Pregnancy | 1 | 2024 | 7230 | 0.080 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 332 | 0.080 |
Why?
| | Diazepam | 1 | 2010 | 32 | 0.080 |
Why?
| | Amiodarone | 1 | 2010 | 31 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2623 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 46 | 0.080 |
Why?
| | Ipratropium | 1 | 2009 | 4 | 0.080 |
Why?
| | Anticoagulants | 1 | 2015 | 746 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2018 | 3647 | 0.070 |
Why?
| | Depression | 2 | 2017 | 1575 | 0.070 |
Why?
| | Paroxetine | 1 | 2009 | 8 | 0.070 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2010 | 144 | 0.070 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2009 | 33 | 0.070 |
Why?
| | Bupropion | 1 | 2009 | 47 | 0.070 |
Why?
| | Mental Disorders | 1 | 2018 | 1148 | 0.070 |
Why?
| | Heart Failure | 1 | 2022 | 2329 | 0.070 |
Why?
| | Mibefradil | 2 | 1998 | 9 | 0.070 |
Why?
| | Time Factors | 4 | 2013 | 7109 | 0.070 |
Why?
| | Fluoxetine | 1 | 2009 | 56 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1498 | 0.070 |
Why?
| | Bronchodilator Agents | 1 | 2009 | 186 | 0.070 |
Why?
| | Fees, Pharmaceutical | 1 | 2008 | 8 | 0.070 |
Why?
| | Internet | 1 | 2013 | 660 | 0.070 |
Why?
| | Telemedicine | 1 | 2017 | 966 | 0.070 |
Why?
| | Prospective Studies | 5 | 2015 | 8123 | 0.060 |
Why?
| | Blood Glucose | 1 | 2017 | 2360 | 0.060 |
Why?
| | Surveys and Questionnaires | 7 | 2018 | 6073 | 0.060 |
Why?
| | Sumatriptan | 1 | 2006 | 6 | 0.060 |
Why?
| | Tryptamines | 1 | 2006 | 5 | 0.060 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 27 | 0.060 |
Why?
| | Financing, Personal | 1 | 2005 | 26 | 0.060 |
Why?
| | Drugs, Generic | 1 | 2005 | 28 | 0.060 |
Why?
| | Hypolipidemic Agents | 2 | 2008 | 89 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2022 | 0.050 |
Why?
| | Triazoles | 1 | 2006 | 190 | 0.050 |
Why?
| | Incidence | 1 | 2011 | 2936 | 0.050 |
Why?
| | Patients | 1 | 2005 | 183 | 0.050 |
Why?
| | Anticholesteremic Agents | 1 | 2005 | 156 | 0.050 |
Why?
| | Medical Records Systems, Computerized | 2 | 2006 | 95 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3347 | 0.050 |
Why?
| | Proton Pump Inhibitors | 1 | 2024 | 101 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1307 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2107 | 0.050 |
Why?
| | Medicaid | 2 | 2017 | 477 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2024 | 248 | 0.050 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 17 | 0.050 |
Why?
| | Primary Prevention | 1 | 2024 | 222 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 928 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2026 | 930 | 0.040 |
Why?
| | Sodium | 1 | 2022 | 196 | 0.040 |
Why?
| | Economics, Pharmaceutical | 1 | 2000 | 10 | 0.040 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 499 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2006 | 11821 | 0.040 |
Why?
| | Medication Systems, Hospital | 1 | 1999 | 5 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 23 | 0.030 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 269 | 0.030 |
Why?
| | Community Health Centers | 1 | 2018 | 59 | 0.030 |
Why?
| | Veterans | 2 | 2001 | 1650 | 0.030 |
Why?
| | Qualitative Research | 1 | 2026 | 1734 | 0.030 |
Why?
| | Outpatient Clinics, Hospital | 1 | 1998 | 80 | 0.030 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2014 | 640 | 0.030 |
Why?
| | Software | 2 | 1999 | 676 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1053 | 0.030 |
Why?
| | Vulnerable Populations | 1 | 2018 | 178 | 0.030 |
Why?
| | Counseling | 1 | 2000 | 406 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 27 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 88 | 0.030 |
Why?
| | Prescription Drug Misuse | 1 | 2017 | 58 | 0.030 |
Why?
| | Health Status | 1 | 2001 | 827 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2015 | 55 | 0.030 |
Why?
| | Logistic Models | 1 | 2000 | 2126 | 0.030 |
Why?
| | Epoetin Alfa | 1 | 2014 | 9 | 0.030 |
Why?
| | Warfarin | 1 | 2015 | 179 | 0.020 |
Why?
| | Longitudinal Studies | 2 | 2014 | 3017 | 0.020 |
Why?
| | Publishing | 1 | 2015 | 117 | 0.020 |
Why?
| | Erythropoietin | 1 | 2014 | 100 | 0.020 |
Why?
| | Pain Management | 1 | 2017 | 421 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1998 | 1064 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 18 | 0.020 |
Why?
| | Drug Overdose | 1 | 2017 | 377 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1038 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2012 | 93 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 517 | 0.020 |
Why?
| | Specialization | 1 | 2013 | 137 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2012 | 97 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1133 | 0.020 |
Why?
| | Education, Pharmacy | 1 | 2013 | 125 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1361 | 0.020 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2010 | 4 | 0.020 |
Why?
| | Thyrotropin | 1 | 2010 | 120 | 0.020 |
Why?
| | Hemorrhage | 1 | 2015 | 825 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2010 | 151 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2009 | 63 | 0.020 |
Why?
| | Data Interpretation, Statistical | 2 | 2001 | 368 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 234 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 634 | 0.020 |
Why?
| | Models, Econometric | 1 | 2008 | 35 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 451 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1665 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 171 | 0.020 |
Why?
| | Cardiology | 1 | 2010 | 363 | 0.020 |
Why?
| | Electrocardiography | 1 | 2010 | 667 | 0.020 |
Why?
| | Analgesics | 1 | 2008 | 230 | 0.010 |
Why?
| | Prevalence | 1 | 2012 | 2861 | 0.010 |
Why?
| | Prognosis | 1 | 2013 | 4351 | 0.010 |
Why?
| | Pain | 1 | 2008 | 790 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11913 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 1999 | 3416 | 0.010 |
Why?
| | Total Quality Management | 1 | 2001 | 59 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2001 | 167 | 0.010 |
Why?
| | Quality-Adjusted Life Years | 1 | 2000 | 122 | 0.010 |
Why?
| | Lipoproteins, LDL | 1 | 2000 | 119 | 0.010 |
Why?
| | Treatment Refusal | 1 | 2000 | 99 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2001 | 219 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2001 | 417 | 0.010 |
Why?
| | Linear Models | 1 | 2001 | 857 | 0.010 |
Why?
| | Medical Records | 1 | 1999 | 193 | 0.010 |
Why?
| | Health Services Research | 1 | 2001 | 390 | 0.010 |
Why?
| | Quality Indicators, Health Care | 1 | 2001 | 343 | 0.010 |
Why?
| | Attitude to Health | 1 | 2001 | 421 | 0.010 |
Why?
| | Child | 1 | 2017 | 22693 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2000 | 770 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2001 | 1763 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1998 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2921 | 0.010 |
Why?
|
|
Billups's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|